【摘要】 目的 檢測B細胞成熟抗原（BCMA）mRNA在系統性紅斑狼瘡（SLE）患者外周血單個核細胞（PBMC）的表達水平，探討BCMA在SLE發病中的意義。 方法 納入2006年1-11月收治的36例SLE患者，同期17例健康志愿者作為對照組，采用半定量RT-PCR法檢測外周血單個核細胞中BCMA mRNA的表達，并與SLE疾病活動指數（SLEDAI）進行相關性分析。 結果 SLE患者組BCMA mRNA表達水平（0.598±0.230）均明顯高于正常對照組（0.411±0.309）（Plt;0.05）。SLE患者BCMA mRNA表達水平與SLEDAI評分無相關性（P=0.590）。 結論 SLE患者BCMA mRNA表達水平的增高，可能在SLE的發病機制中具有一定的作用。【Abstract】 Objective To detect the mRNA expression of B-cell maturation antigen (BCMA) in peripheral blood mononuclear cells (PBMC) in patients with systemic lupus erythematosus (SLE), and explore the role of BCMA in the pathogenesis of SLE. Methods From January 2006 to November 2006 the expression of BCMA mRNA in PBMC of 36 patients with SLE and 17 normal controls were measured by half-quantitative RT-PCR. The linear correlation between the expression of BCMA mRNA and SLE disease activity index (SLEDAI) was assessed. Results The level of BCMA mRNA (0.598±0.230) in PBMC significantly increased in SLE patients compared with that in the normal controls (0.411±0.309) (Plt;0.05). The expression of BCMA mRNA in SLE patients showed no correlation with SLEDAI score (P=0.590). Conclusion The results suggest that the expression of BCMA mRNA might play an important role in the pathogenesis of SLE.
目的:觀察白芍總苷(TGP)聯合甲氨喋呤(MTX)和柳氮磺吡啶(SASP)治療強直性脊柱炎(AS)療效和安全性。方法:58例符合強直性脊柱炎標準的患者隨機納入2組:治療組:29例,口服白芍總苷+甲氨喋呤+柳氮磺吡啶;對照組:29例,口服甲氨喋呤+柳氮磺吡啶,兩組療程均為3月。結果:經3月治療,兩組間Schober實驗、胸廓擴張度、晨僵持續時間、血沉(ESR)及C反應蛋白(CRP)等5項指標較治療前均顯著降低(Plt;0.01),但治療組上述指標改善值優于對照組,差異分別有顯著意義(Plt;0.05)或極顯著意義(Plt;0.01);治療組不良反應發生率明顯少于對照組(Plt;0.05)。結論:白芍總苷聯合甲氨喋呤和柳氮磺吡啶是治療強直性脊柱炎安全有效方法。